OVARIAN CANCER

This trial tests a personalized mRNA vaccine called NeoOVIV in people with stage II or III ovarian cancer who have had surgery. The vaccine is designed to teach the immune system to recognize and attack cancer cells. Participants receive the vaccine alongside standard chemotherap…

This phase 2 trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery can improve outcomes for people with advanced ovarian cancer. Participants receive 3-4 cycles of the combination, followed by surgery to rem…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This early-phase trial tests a one-time treatment called OPB-201, where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called PRAME. The study will enroll 30 adults with recurrent endometrial cancer or platinum-…

This early-phase trial tests a new cell therapy called NK521 for people with advanced liver cancer (hepatocellular carcinoma) or ovarian cancer that has not responded to standard treatments. NK521 are natural killer (NK) cells that have been gene-edited to remove three proteins t…

This trial tests whether fluzoparib plus bevacizumab works as well as the standard olaparib plus bevacizumab for maintenance therapy in women with HRD-positive advanced ovarian cancer after initial chemotherapy. The study enrolls about 120 participants and tracks how long they st…

This study tests a new drug, ubamatamab, combined with standard chemotherapy drugs (carboplatin, paclitaxel, and bevacizumab) in 43 people with advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if the combination is safe and can shrink tum…

This phase 2 trial is testing a new, intensive treatment plan for 28 people with advanced ovarian cancer. The approach combines chemotherapy given into the abdomen and vein, a special vaccine made from the patient's own immune cells, and the immunotherapy drug Keytruda. The goal …

This early-stage trial tests a new drug called ONC-783 in 20 people with advanced solid tumors, including colorectal, ovarian, pancreatic, or breast cancer. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goal is to find a safe d…

This large Phase 3 trial will test a new drug called Rina-S, alone or with bevacizumab, against standard platinum-based chemotherapy for women with ovarian cancer that has returned after initial treatment. About 688 participants will be randomly assigned to receive either the new…

This early-stage trial tests two experimental drugs, XmAb541 and XmAb808, in people with advanced ovarian cancer that has come back or spread. The main goal is to see if the combination is safe and find the best dose. About 90 adults with a specific tumor marker (CLDN6) will take…

This early-stage study tests two drugs, CKD-215 and D215, in 24 adults aged 19-75 with advanced BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer. The goal is to compare how the body processes each drug and check for side effects. Participants will receive both d…

This study tests a combination of three drugs (Benmelstobart, Anlotinib, and low-dose Cyclophosphamide) in 40 women whose ovarian, fallopian tube, or peritoneal cancer has come back. The goal is to see if this mix can keep the cancer from growing for longer. Participants must be …

This study tests whether giving a dye called Cytalux a few days before surgery works as well as giving it closer to the operation. The dye makes tumors glow under a special light, helping surgeons remove them more completely. About 106 adults with suspected lung cancer or confirm…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This early-phase study tests a new cell therapy called KT032 in 24 adults with advanced solid tumors (ovarian, mesothelioma, colon cancer) that have spread to the abdomen and haven't responded to standard treatments. The main goal is to check safety and find the best dose, while …

This study tests a daily pill called hetrombopag to see if it can safely raise low platelet counts in women with gynecological cancers (like ovarian or cervical cancer) after chemotherapy. About 244 women whose platelets dropped too low will take the drug to help them complete th…

This study compares a single chemotherapy drug (paclitaxel) to the standard two-drug combo (paclitaxel plus carboplatin) as initial treatment before surgery for advanced ovarian cancer. It is for patients whose tumors have high levels of a protein called PARK2, which may make the…

This study looks at whether a blood test score (KELIM) can help doctors decide the best time for surgery in people with advanced ovarian cancer. After three rounds of chemotherapy, those with a good score will have surgery right away, while those with a poor score will get more c…

This study tests whether a combination of two drugs (fluzoparib and famitinib) can help keep advanced ovarian cancer from returning after successful initial chemotherapy. About 43 women with stage III-IV ovarian cancer who responded to platinum-based chemo will take these pills d…

This Phase 2 trial tests a new drug called JPI-547 combined with bevacizumab in 81 women with relapsed ovarian cancer who have already been treated with PARP inhibitors and responded to platinum chemotherapy. The study aims to find the best dose and see if the combination helps k…

This study tests two drug combinations (fluzoparib plus famitinib or fluzoparib plus SHR-1701) given before surgery to shrink advanced ovarian cancer in 104 women whose tumors cannot be fully removed right away. The goal is to see how well these treatments work and how safe they …

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This phase 2 trial tests a combination of three drugs—liposomal irinotecan, sintilimab, and anlotinib—in 36 people with recurrent or persistent ovarian clear cell carcinoma. The goal is to see if the treatment can shrink tumors and control the disease. Participants must have alre…

This study tests whether using an AI tool to analyze a patient's body composition from a CT scan can help doctors personalize chemotherapy dosing. The goal is to reduce severe side effects like low white blood cell counts in women with endometrial or ovarian cancer. About 294 par…

This study tests a drug called sacituzumab in 22 people with a rare and aggressive type of ovarian cancer (clear cell carcinoma) that has worsened after immunotherapy. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to see how man…

This study looks at whether a specialized blood test can detect tiny bits of cancer DNA in the blood of women with advanced ovarian cancer after they finish initial treatment. Researchers will follow 300 women for up to 3 years, taking blood samples at key times. The goal is to s…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study will test a new blood test that looks for DNA changes to detect ovarian cancer, especially in early stages. Researchers will compare test results from 1,000 women with and without ovarian cancer to see how accurate it is. If it works well, it could lead to a simple scr…

This study is testing a new medical device that gently collects cells from the vagina to look for signs of ovarian and endometrial cancers. The goal is to see if this less invasive method can accurately detect these cancers compared to standard tests. About 300 women, some with c…

This study tests whether artificial intelligence (AI) can predict the type of ovarian cancer and how well surgery might work by analyzing videos from a diagnostic laparoscopy. Researchers will collect videos from 100 women with advanced ovarian cancer and train an AI to recognize…

This study compares a new DNA sequencing platform (MGI) against the current standard (Illumina) for diagnosing hereditary cancers like breast and ovarian cancer, Lynch syndrome, and intestinal polyposis. Researchers will analyze 248 patient samples using both platforms to see if …

This study tests a new blood test called OCS that uses exosome technology to monitor for ovarian cancer recurrence. It focuses on patients whose CA125 levels were normal before initial treatment, making standard monitoring difficult. The trial will enroll 32 women with stage I-IV…

This study tests whether electroacupuncture (using mild electric pulses on needles) plus tiny thumbtack needles can prevent nerve damage caused by chemotherapy in people with early-stage cancer. About 278 patients with breast, stomach, bowel, lung, or ovarian cancer will receive …

This study looks at whether a prehabilitation program—including physical therapy, dietary advice, and emotional support—given before major cancer surgery can reduce deaths and serious complications within 30 days after the operation. About 180 adults with cancers of the pancreas,…

This pilot trial will test whether a prehabilitation program (exercise, protein drinks, breathing exercises, and coaching) is feasible for women awaiting ovarian cancer surgery. It compares in-person delivery, remote delivery via a web app, and standard education-only care. The s…

This study tests whether N-Acetyl-Cysteine (NAC), a supplement, can reduce chemotherapy-related cognitive impairment (often called 'chemo brain') in ovarian cancer patients. About 102 postmenopausal women with advanced ovarian cancer receiving platinum-based chemotherapy will tak…

This study looks at whether hand and foot exercises can reduce nerve pain (numbness, tingling) and improve quality of life in adults aged 65+ with gynecological cancer who are on chemotherapy. About 74 participants will do these exercises to see if they help with chemotherapy sid…

This study tests a Traditional Chinese Medicine (TCM) regimen to help ovarian cancer patients with common symptoms like trouble sleeping, fatigue, sadness, and distress. About 316 participants will receive either the TCM regimen or a placebo to see if it improves these symptoms. …

This study looks at whether an educational video can help people with certain cancers make informed choices about genetic testing. Participants will take a survey, watch a short video, and then take another survey to see if their knowledge and attitudes changed. The goal is to se…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study looks at whether a blood test can predict how well certain cancer drugs (PARP inhibitors) work in people with advanced breast, prostate, ovarian, or pancreatic cancer. Researchers will collect blood and tumor samples from 300 adults to analyze cancer cells and their DN…

This study looks at how well different labs agree when testing for a protein called FRa in stored tumor samples from women with ovarian cancer. About 1,000 women's archived tissue will be tested, but no new treatments or visits are needed. The goal is to improve consistency of FR…

This study is testing a new questionnaire (called the QLQ-OV39) to see how well it measures quality of life in people with ovarian cancer. About 50 adults with early or advanced ovarian cancer will fill out the questionnaire and give feedback. The goal is to make sure the questio…

This study is for young adults (ages 21-45) who had certain cancers as teens or young adults. Researchers are adapting a program that helps survivors manage their health after cancer treatment. The goal is to see if this program improves survivors' confidence and ability to handl…

This study looks at how well different methods—imaging, a small camera surgery (laparoscopy), and open surgery (laparotomy)—agree on whether an ovarian mass can be completely removed. It will involve 28 women with primary ovarian cancer. The goal is to see if less invasive method…

This study uses a special 3D ultrasound to look at blood flow inside cervical and ovarian tumors. Researchers want to see if blood flow patterns can help tell the difference between cancer and pre-cancer, and if they can predict how well patients will do over time. About 100 adul…

This study checks if surgeons can tell key details about ovarian cancer by looking at images from a camera inside the belly. About 70-80 surgeons will review pictures from 19 patients and guess the cancer type and growth pattern. The goal is to see if visual clues can help plan t…

This study examines if different eating patterns, especially low-carbohydrate diets, are linked to better outcomes in women with high-grade serous ovarian cancer who are on maintenance therapy with PARP inhibitors. Researchers will review medical records and survey 600 patients f…

This study looks back at the medical records of 200 people treated for gynecological cancers (like ovarian, cervical, or uterine cancer) at Assiut University Hospital between 2022 and 2025. The goal is to measure how long patients survive after diagnosis and compare those numbers…